EUVIMEDEUVIMED entdecken
Crossref

Development of a HEp2‐CDX Mouse Model With Sustained High RSV Viral Loads for Robust Antiviral Therapeutic Evaluation

Jinwei Yuan iD, Duo Xu, Xiaohong Liao, Chengxing Zhou, Qiong Zhang, Hui Liao, Minglei Liu, Zhoulang Wang, Jing Dai, Ren Cao, Qiuru Li, Hui Cai und 2 weitere

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Jinwei Yuan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou National Laboratory, Guangzhou, China. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Viral Load, Disease Models, Animal, Antiviral Agents. Die Arbeit nennt 35 Literaturangaben. Gefördert von: This study was supported by the Scientific Research Initiation Fund to Rong Zhou (No. YW-YWYMO501), a Major Project of the Guangzhou National Laboratory Grant….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The respiratory syncytial virus (RSV) is a predominant pathogen that causes lower respiratory tract infections and is widespread among infants and the elderly. Antibodies and antiviral drugs are effective treatment strategies for RSV, but their efficacy varies among different animal models. Here, we present a mouse model constructed using HEp‐2 cell line‐derived xenograft (HEp2‐CDX) technology. The HEp2‐CDX mouse model sustained high viral loads following both intratumoral and intravenous inoculation with RSV. The average peak titers rapidly reached 1 × 10 7 copies/g in lung tissues and 6 × 10 9 copies/g in the tumor tissues over a period up to 5 days. Furthermore, the addition of a clinical monoclonal antibody (nirsevimab) and an antiviral drug (ziresovir) showed strong antiviral activity within this animal model. These findings suggest that HEp2‐CDX mice, which enable stable RSV infection and replication, serve as useful models for evaluating antiviral therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsViral LoadDisease Models, AnimalAntiviral AgentsRespiratory Syncytial Virus, HumanRespiratory Syncytial VirusesAnimalsMiceHumansFemaleLungCell Line, TumorMice, Inbred BALB CVirus Replication

Stichwörter der Autor:innen

antiviral agentsmouse model of infectionrespiratory syncytial virus

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Guangzhou National Laboratory, Guangzhou, China.
  • School of Pharmaceutical Sciences, Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
  • State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou,…

ORCID-Profile: Jinwei Yuan, Rong Zhou, Xingui Tian

Förderung

  • This study was supported by the Scientific Research Initiation Fund to Rong Zhou (No. YW-YWYMO501), a Major Project of the Guangzhou National Laboratory Grant…

Zitieren

APA

Yuan, J., Xu, D., Liao, X., Zhou, C., Zhang, Q., Liao, H., Liu, M., Wang, Z., Dai, J., Cao, R., Li, Q., Cai, H., Zhou, R., & Tian, X. (2025). Development of a HEp2‐CDX Mouse Model With Sustained High RSV Viral Loads for Robust Antiviral Therapeutic Evaluation. Journal of Medical Virology. https://doi.org/10.1002/jmv.70601

Vancouver

Yuan J, Xu D, Liao X, Zhou C, Zhang Q, Liao H, et al. Development of a HEp2‐CDX Mouse Model With Sustained High RSV Viral Loads for Robust Antiviral Therapeutic Evaluation. Journal of Medical Virology. 2025. doi:10.1002/jmv.70601

BibTeX
@article{Yuan2025,
  author = {Yuan, Jinwei and Xu, Duo and Liao, Xiaohong and Zhou, Chengxing and Zhang, Qiong and Liao, Hui and Liu, Minglei and Wang, Zhoulang and Dai, Jing and Cao, Ren and Li, Qiuru and Cai, Hui and Zhou, Rong and Tian, Xingui},
  title = {Development of a HEp2‐CDX Mouse Model With Sustained High RSV Viral Loads for Robust Antiviral Therapeutic Evaluation},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70601}
}
Kostenlos starten →